Compare CIO & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIO | DRTS |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.5M | 300.2M |
| IPO Year | 2014 | N/A |
| Metric | CIO | DRTS |
|---|---|---|
| Price | $6.96 | $4.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 525.1K | 78.3K |
| Earning Date | 02-19-2026 | 11-20-2025 |
| Dividend Yield | ★ 4.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $163,795,000.00 | N/A |
| Revenue This Year | $0.32 | N/A |
| Revenue Next Year | $3.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.19 | $2.30 |
| 52 Week High | $7.01 | $4.69 |
| Indicator | CIO | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 63.51 | 60.27 |
| Support Level | $6.79 | $3.84 |
| Resistance Level | $6.89 | $4.28 |
| Average True Range (ATR) | 0.04 | 0.28 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 92.11 | 76.64 |
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. Its properties includes: Pima Center, SanTan, Park Tower, Intellicenter, Intellicenter, Denver Tech, Canyon Park, AmberGlen and many. The company own these office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.